Article: Efficacy and Safety of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist in Real-Life: A Case Series of Patients in Maintenance Incremental Hemodialysis.
Case reports in nephrology and dialysis
2022 Volume 12, Issue 3, Page(s) 238–247
Abstract: The glucagon-like peptide-1 receptor agonists (GLP-1RA) are among the newest treatment options available for managing of type 2 diabetes mellitus and slowing the progression of diabetes kidney disease (DKD). Subcutaneous (SC) semaglutide ( ... ...
Abstract | The glucagon-like peptide-1 receptor agonists (GLP-1RA) are among the newest treatment options available for managing of type 2 diabetes mellitus and slowing the progression of diabetes kidney disease (DKD). Subcutaneous (SC) semaglutide (Ozempic |
---|---|
Language | English |
Publishing date | 2022-11-22 |
Publishing country | Switzerland |
Document type | Case Reports |
ZDB-ID | 2809879-1 |
ISSN | 2296-9705 |
ISSN | 2296-9705 |
DOI | 10.1159/000527919 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.